Zacks Investment Research upgraded shares of IntriCon (NASDAQ:IIN) from a hold rating to a buy rating in a research report sent to investors on Thursday, March 8th. Zacks Investment Research currently has $21.00 price objective on the technology company’s stock.
According to Zacks, “IntriCon designs, develops, engineers and manufactures microminiaturized medical and electronic products. The Company supplies microminiaturized components, systems and molded plastic parts, primarily to the hearing instrument manufacturing industry, as well as the computer, government, electronics, telecommunications and medical equipment industries. The Company has facilities in the United States, Asia and Europe. “
Separately, TheStreet upgraded shares of IntriCon from a c rating to a b- rating in a research report on Wednesday, November 8th.
Shares of IntriCon (IIN) opened at $18.25 on Thursday. The company has a quick ratio of 0.54, a current ratio of 1.45 and a debt-to-equity ratio of 0.34. The stock has a market cap of $125.15, a PE ratio of 64.46, a P/E/G ratio of 1.94 and a beta of 0.16. IntriCon has a one year low of $6.05 and a one year high of $24.00.
IntriCon (NASDAQ:IIN) last issued its quarterly earnings data on Monday, February 12th. The technology company reported $0.07 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.06 by $0.01. The firm had revenue of $22.23 million during the quarter. IntriCon had a net margin of 2.04% and a return on equity of 10.82%. equities analysts predict that IntriCon will post 0.62 earnings per share for the current fiscal year.
Institutional investors and hedge funds have recently made changes to their positions in the company. Prescott Group Capital Management L.L.C. bought a new position in shares of IntriCon during the fourth quarter worth approximately $366,000. Northern Trust Corp increased its holdings in shares of IntriCon by 10.2% during the second quarter. Northern Trust Corp now owns 21,040 shares of the technology company’s stock worth $172,000 after purchasing an additional 1,942 shares during the period. Vanguard Group Inc. increased its holdings in shares of IntriCon by 5.8% during the second quarter. Vanguard Group Inc. now owns 21,813 shares of the technology company’s stock worth $174,000 after purchasing an additional 1,200 shares during the period. Algert Global LLC bought a new position in shares of IntriCon during the third quarter worth approximately $396,000. Finally, EAM Investors LLC bought a new position in shares of IntriCon during the third quarter worth approximately $588,000. 37.69% of the stock is currently owned by institutional investors.
TRADEMARK VIOLATION NOTICE: “IntriCon (NASDAQ:IIN) Upgraded by Zacks Investment Research to Buy” was originally reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this article on another site, it was illegally copied and republished in violation of US and international copyright and trademark law. The correct version of this article can be viewed at https://www.dispatchtribunal.com/2018/03/15/intricon-iin-upgraded-by-zacks-investment-research-to-buy.html.
IntriCon Company Profile
IntriCon Corporation is engaged in designing, developing, engineering, manufacturing and distributing body-worn devices. The Company operates through body-worn device segment. The Company serves the body-worn device market by designing, developing, engineering and manufacturing micro-miniature products, microelectronics, micro-mechanical assemblies, complete assemblies and software solutions, primarily for the value hearing health market, the medical bio-telemetry market and the professional audio communication market.
Get a free copy of the Zacks research report on IntriCon (IIN)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for IntriCon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IntriCon and related companies with MarketBeat.com's FREE daily email newsletter.